Physical Stability of Drugs: Linking Quality-By-Design (QbD) And Process Analytical Technology (PAT)

Reference

1. Byrn SR, Pfeiffer RR, Stowell JG. Solid-State Chemistry of Drugs. 2nd ed. West Lafayette, IN: SSCI, Inc.; 1999.
2. Brittain HG. Polymorphism in Pharmaceutical Solids. 2nd ed. New York, NY: Informa Healthcare; 2009.
3. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.
4. International Council for Harmonisation. ICH Q9: Quality Risk Management. Geneva: ICH; 2006.
5. Food and Drug Administration. Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Rockville, MD: FDA; 2004.
6. Wu H, Khan MA, Khan S. Quality-by-Design (QbD): an integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. Int J Pharm. 2011;405(1-2):63-78.
7. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
8. Morris KR, et al. Compaction-induced solid-state transitions and strategies to mitigate them. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. 2nd ed. New York, NY: Informa Healthcare; 2009.
9. Yu L. Amorphous pharmaceutical solids: a review of the state of the art. J Pharm Sci. 2001;90(11):1621-1634.
10. Hancock BC, Shamblin SL, Zografi E. What is the True Solubility Advantage for Amorphous Pharmaceuticals? Mol Pharm. 2002;1(1):52-59.
11. Hancock BC, Zografi G. The relationship between the glass transition temperature and the mechanical properties of amorphous pharmaceuticals. Int J Pharm. 1997;142(2):299-307.
12. Nurzy?ska K, et al. Long-term amorphous drug stability predictions using measurable properties. Mol Pharm. 2015;12(8):2765–2779.
13. Chen Y, et al. Pharmaceutical protein solids: drying, formulation, and physical stability. Pharm Res. 2009;26(10):2251–2261.
14. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397-404.
15. Khorasani MT, et al. Real-time particle size analysis using focused beam reflectance measurement as a process analytical technology tool for a continuous granulation–drying–milling process. J Pharm Sci. 2013;102(6):1798-1806.
16. Brittain HG, Fiese EF. Effects of pharmaceutical processing on drug polymorphs and solvates. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. 2nd ed. New York, NY: Informa Healthcare; 2009.
17. Qian F, Bogner RH. Solid-state NMR and other techniques for characterization of polymorphism and amorphous content. J Pharm Sci. 2005;94(8):1687–1701.
18. Wenslow R, et al. XRPD and in-line X-ray applications for monitoring crystallinity during manufacture. J Pharm Biomed Anal. 2004;35(4):723–733.
19. Morris KR, Good DL, Newman AW. Polymorphic transformations during compression and processing: implications for formulation. J Pharm Sci. 2002;91(9):1987-1996.
20. Trasi NS, Taylor LS. Moisture sorption, plasticization, and crystallization kinetics of amorphous dispersions. J Pharm Sci. 2015;104(12):4018–4028.
21. Chemometric Methods for Spectroscopy-Based Pharmaceutical Analysis. Front Chem. 2018; 6:576.
22. The Role of Spectroscopy in Modern Pharmaceutical Quality Control. J Basic Clin Pharm. 2018; 9:13072.
23. Wenslow R, et al. In-line X-ray applications for monitoring crystallinity during manufacture. J Pharm Biomed Anal. 2004;35(4):723–733.
24. Chen Y, et al. Pharmaceutical protein solids: drying, formulation, and physical stability. Pharm Res. 2021; 38:102.
25. Mallet L, et al. The application of thermal analysis to the pharmaceutical industry. Am Pharm Rev. 2010;13(2):16-24.
26. The Application of Thermal Analysis to the Pharmaceutical Industry. Am Pharm Rev. 2010;13(2):16-24.
27. Particle Characterization for Pharmaceuticals. Pharmaceutics. 2016;8(1):15-28.
28. Wu H, et al. Quality-by-Design (QbD): an integrated process analytical approach. Int J Pharm. 2011;415(1-2):3–21.
29. Terahertz spectroscopy: a powerful new tool for the chemical sciences? Chem Soc Rev. 2012;41(7):2939-2949.
30. Model-Based PAT for Quality Management in Pharmaceuticals Freeze-Drying: State of the Art. Front Bioeng Biotechnol. 2017; 5:5.
31. Assessment of Recent Process Analytical Technology (PAT) Trends: A Multiauthor Review. Drug Dev Ind Pharm. 2018;44(1):1-16.
32. Sun D, et al. Process analytical technologies for pharmaceutical crystallization: a review. J Control Release. 2019; 292:131–142.
33. Crowley MM, et al. Spray drying of pharmaceuticals. In: Pharmaceutical Process Analytical Technology. 2nd ed. CRC Press; 2017.
34. Murdande SB, et al. Role of polymer glass transition temperature and molecular mobility in stabilization of amorphous solid dispersions. J Pharm Sci. 2011;100(11):4759-4771.
35. Plewa J, et al. Process analytical technology and quality by design. In: Pharmaceutical Process Analytical Technology. 2nd ed. CRC Press; 2017.
36. O’Driscoll W, et al. Challenges and opportunities for process analytical technology in pharmaceutical manufacturing. J Pharm Sci. 2013;102(9):2960–2972.
37. Rantanen J, et al. The role of process analytical technology in drug product development. Pharmaceutics. 2016;8(4):35.